{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:25:17Z","timestamp":1786116317051,"version":"build-2736575974"},"reference-count":17,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Background: The role of primary tumor resection (PTR) in patients with de novo stage IV colorectal cancer remains controversial, particularly in the context of patient selection and tumor biology. This study aimed to evaluate the association between PTR and survival outcomes and to identify clinical, molecular, and inflammatory-nutritional prognostic factors in patients with de novo stage IV colorectal cancer. Methods: Medical records of 204 patients with de novo stage IV colorectal adenocarcinoma treated at Ankara Etlik City Hospital from December 2022 to December 2025 were reviewed retrospectively. Patients were grouped according to PTR status. Baseline clinicopathological features, molecular tumor profile, metastatic disease extent, treatment characteristics, and inflammatory-nutritional markers were recorded. Survival outcomes were assessed in terms of progression-free survival (PFS) and overall survival (OS) using the Kaplan\u2013Meier method and Cox proportional hazards regression models, as well as 1:1 propensity score matching and sensitivity analyses. Results: PTR was performed in 114 patients (55.9%), while 90 patients (44.1%) did not undergo PTR. Patients who underwent PTR were younger, had better Eastern Cooperative Oncology Group (ECOG) performance status, and more frequently had single-organ metastatic disease. In the unmatched cohort, patients who underwent PTR had longer median PFS and OS than those without PTR (15.88 vs. 11.03 months and 16.14 vs. 11.54 months, respectively; both log-rank p &lt; 0.001). In the adjusted Cox models, PTR corresponded to lower risks of progression (hazard ratio [HR]: 0.50; 95% confidence interval [CI]: 0.34\u20130.74; p &lt; 0.001) and death (HR: 0.48; 95% CI: 0.30\u20130.77; p = 0.002), whereas BRAF mutation showed higher risks of progression (HR: 3.00; 95% CI: 1.70\u20135.29; p &lt; 0.001) and death (HR: 3.42; 95% CI: 1.83\u20136.38; p &lt; 0.001). In the propensity score\u2013matched cohort comprising 50 matched pairs, PTR remained associated with a lower risk of progression or death (HR: 0.59; 95% CI: 0.40\u20130.87; p = 0.007), whereas its association with OS was not statistically significant (HR: 0.69; 95% CI: 0.42\u20131.13; p = 0.141). Sensitivity analyses generally yielded estimates favoring PTR, although the statistical significance of the association with OS varied across analyses. Patients with higher prognostic nutritional index (PNI) values showed more favorable survival outcomes. Conclusions: In this retrospective cohort, PTR was consistently associated with longer PFS, whereas its association with OS was less robust across the adjusted analyses. Because these patients had a more favorable baseline profile, these associations should be viewed with caution and in relation to patient selection. BRAF mutation and PNI emerged as important prognostic factors, supporting a multidimensional approach to survival assessment that incorporates metastatic disease burden, tumor biology, and inflammatory-nutritional status.<\/jats:p>","DOI":"10.3390\/curroncol33080467","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:48:08Z","timestamp":1785948488000},"page":"467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Primary Tumor Resection with Survival in De Novo Stage IV Colorectal Cancer: A Retrospective Cohort Study with Propensity Score Matching"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-5861","authenticated-orcid":false,"given":"Hatice","family":"Ayy\u0131ld\u0131z Sevim","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0698-777X","authenticated-orcid":false,"given":"Galip Can","family":"Uyar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1561-9346","authenticated-orcid":false,"given":"Hayriye","family":"\u015eahinli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/jnci\/djh275","article-title":"Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging","volume":"96","author":"Maggard","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11767","DOI":"10.3748\/wjg.v21.i41.11767","article-title":"Colorectal cancer: Metastases to a single organ","volume":"21","author":"Vatandoust","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rumpold, H., Nieders\u00fc\u00df-Beke, D., Heiler, C., Falch, D., Wundsam, H.V., Metz-Gercek, S., Piringer, G., and Thaler, J. (2020). Prediction of mortality in metastatic colorectal cancer in a real-life population: A multicenter explorative analysis. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07656-w"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejso.2014.02.236","article-title":"Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience","volume":"40","author":"Neuzillet","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.20.02447","article-title":"Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): A randomized clinical trial","volume":"39","author":"Kanemitsu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.23.01540","article-title":"Primary tumor resection before systemic therapy in patients with colon cancer and unresectable metastases: Combined results of the SYNCHRONOUS and CCRe-IV trials","volume":"42","author":"Rahbari","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101820","DOI":"10.1016\/j.suronc.2022.101820","article-title":"Primary tumor resection in patients with unresectable colorectal cancer with synchronous metastases could improve the activity of poly-chemotherapy: A trial-level meta-analysis","volume":"44","author":"Colloca","year":"2022","journal-title":"Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00423-024-03414-9","article-title":"Primary tumor resection for asymptomatic colorectal cancer patients with synchronous unresectable metastases: A meta-analysis of randomized controlled trials and case-matched studies","volume":"409","author":"Huang","year":"2024","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_11","first-page":"1489","article-title":"Targeting BRAF V600E in metastatic colorectal cancer: Where are we today?","volume":"16","author":"Guerrero","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sutherland, R.L., Boyne, D.J., Brenner, D.R., and Cheung, W.Y. (2023). The impact of BRAF mutation status on survival outcomes and treatment patterns among metastatic colorectal cancer patients in Alberta, Canada. Cancers, 15.","DOI":"10.3390\/cancers15245748"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100795","DOI":"10.1016\/j.tranon.2020.100795","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"13","author":"Roviello","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00432-014-1714-3","article-title":"The prognostic significance of the prognostic nutritional index in cancer: A systematic review and meta-analysis","volume":"140","author":"Sun","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Xie, H., Wei, L., Yuan, G., Liu, M., Tang, S., and Gan, J. (2022). Prognostic value of prognostic nutritional index in patients with colorectal cancer undergoing surgical treatment. Front. Nutr., 9.","DOI":"10.3389\/fnut.2022.794489"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2013.54.9329","article-title":"Association of age with survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program","volume":"32","author":"Lieu","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s12094-025-03860-x","article-title":"2025 Updated version v1.0 SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)","volume":"27","author":"Alonso","year":"2025","journal-title":"Clin. Transl. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:05:31Z","timestamp":1786007131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080467"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080467","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}